Shopping Cart
- Remove All
Your shopping cart is currently empty
BMS 299897
Catalog No. T14673Cas No. 290315-45-6
BMS 299897 is a sulfonamide γ-secretase inhibitor with an IC50 of 7 nM for inhibiting Aβ production in HEK293 cells stably overexpressing amyloid precursor protein (APP).
BMS 299897
Catalog No. T14673Cas No. 290315-45-6
BMS 299897 is a sulfonamide γ-secretase inhibitor with an IC50 of 7 nM for inhibiting Aβ production in HEK293 cells stably overexpressing amyloid precursor protein (APP).
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $52 | In Stock | |
| 10 mg | $97 | In Stock | |
| 25 mg | $178 | In Stock | |
| 50 mg | Inquiry | In Stock | |
| 1 mL x 10 mM (in DMSO) | $59 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "BMS 299897"
Valproic Acid
Cited
VPA, Sodium valproate, Depakine, 2-Propylvaleric Acid, 2-Propylpentanoic Acid
T706499-66-1
Valproic Acid (2-Propylpentanoic Acid) is an HDAC inhibitor that inhibits HDAC1 activity, induces HDAC2 degradation, and is orally active. Valproic Acid can be used in epilepsy and bipolar disorder research.
- $50
Size
QTY
CitedRutin Cited
Rutoside, Quercetin 3-O-rutinoside
T0795153-18-4
Rutin (Quercetin 3-O-rutinoside), a flavonoid, has a variety of biological activities including antiallergic, anti-inflammatory, antiproliferative, and anticarcinogenic properties.
- $36
Size
QTY
CitedValproic acid sodium salt Cited
Sodium Valproate
T16021069-66-5
Valproic acid sodium salt (Sodium Valproate) is the sodium salt form of valproic acid with anti-epileptic activity. Valproic acid sodium salt is converted into its active form, valproate ion, in blood. Although the mechanism of action remains to be elucidated, Valproic acid sodium salt increases concentrations of gamma-aminobutyric acid (GABA) in the brain, probably due to inhibition of the enzymes responsible for the catabolism of GABA. This potentiates the synaptic actions of GABA. Valproic acid sodium salt may also affect potassium channels, thereby creating a direct membrane-stabilizing effect.
- $42
Size
QTY
CitedDeferoxamine Mesylate Cited
DFOM, DFO, Desferrioxamine B mesylate, desferrioxamine B
T1637138-14-7
Deferoxamine Mesylate (DFOM) is an iron chelator and ferroptosis inhibitor. Deferoxamine Mesylate binds free iron into a stable complex and reduces iron accumulation. Deferoxamine Mesylate up-regulates HIF-1α levels and induces apoptosis.
- $31
Size
QTY
CitedCarvacrol
O-Thymol, Karvakrol, cymophenol
T4S1990499-75-2
1. Carvacrol (O-Thymol) presents anxiolytic effects. 2. 5-Isopropyl-2-methylphenol presents antinociceptive activity. 3. Carvacrol presents antidepressant effects, seems to be dependent on its interaction with the dopaminergic system, but not with the serotonergic and noradrenergic systems.
- $42
Size
QTY
Tramiprosate
Homotaurine, Alzhemed, 3-Amino-1-propanesulfonic acid
T08833687-18-1
Tramiprosate (Alzhemed) is an orally active, blood-brain-barrier-crossing, naturally occurring amino acid found in a variety of red seaweeds that binds soluble Aβ and maintains it in a non-protofibrillar form.It is a GABA analog with neuroprotective, anticonvulsant, and antihypertensive activity.
- $42
Size
QTY
Notoginsenoside R1
Sanqi glucoside R1, Sanchinoside R1
T296180418-24-2
Notoginsenoside R1 (Sanchinoside R1) has been shown to exhibit antioxidant, antiapoptotic, anti-inflammatory, and immune-stimulatory properties.
- $63
Size
QTY
Geniposide
T221224512-63-8
Geniposide is an iridoid glycoside with a variety of biological activities including neuroprotective, anti-diabetic, antiproliferative, and antioxidative activity. Geniposide has been shown to regulate Nrf2 translocation.
- $60
Size
QTY
Dihydroergocristine mesylate
DHEC (mesylate)
T1104324730-10-7
Dihydroergocristine mesylate (DHEC (mesylate))(DHEC mesylate) is the methanesulfonic acid salt of dihydroergocristine. It has been used as the for the symptomatic treatment of mental deterioration associated with cerebrovascular insufficiency and in peripheral vascular disease. Dihydroergocristine mesylate is a inhibitor of γ-secretase (GSI), , reduces the production of the Alzheimer's disease amyloid-β peptides, binds directly to γ-secretase and Nicastrin with equilibrium dissociation constants (Kd) of 25.7 nM and 9.8 μM, respectively[1]. It is also a component of ergoloid mesylate (codergocrine mesilate), a mixture of ergot alkaloid derivatives that is used as a vasodilator and has shown mild benefits in the treatment of vascular dementia. It has a role as a vasodilator agent, an alpha-adrenergic antagonist and a geroprotector. It contains a dihydroergocristine.
- $48
Size
QTY
Anle138b
T5447882697-00-9
Anle138b: a novel oligomer modulator for disease-modifying therapy of neurodegenerative diseases such as prion and Parkinson's disease
- $77
Size
QTY
CB-103
T12246218457-67-1
CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity.
- $33
Size
QTY
Select Batch
Purity:100%
Contact us for more batch information
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.Product Introduction
Bioactivity
Chemical Properties
| Description | BMS 299897 is a sulfonamide γ-secretase inhibitor with an IC50 of 7 nM for inhibiting Aβ production in HEK293 cells stably overexpressing amyloid precursor protein (APP). |
| Targets&IC50 | β-Amyloid (HEK293 cells):7 nM, β-Amyloid (HEK293 cells):7 nM |
| In vitro | BMS-299897 (1 μM) decreases these peptides to levels ranging from 20 to 50% of the vehicle control. Furthermore, it leads to a reduction in the proportion of QD-BDNF signals moving in the retrograde direction (p=0.0198) while concurrently increasing the proportion of signals moving in the anterograde direction (p=0.0147).[2] |
| In vivo | BMS-299897 (0.1-1 nmol/mouse; male Swiss mice; one week) blocks the increase in Aβ1-42 content and decreases Aβ1-40 levels significantly. The compound does not affect the Aβ25-35-induced increase in hippocampal lipid peroxidation. Behaviorally, BMS-299897 blocks the Aβ25-35-induced deficits in spontaneous alternation or novel object recognition, using a 1 h intertrial time interval. The co-administration of the γ-secretase inhibitor BMS-299897, in the 0.1-1 μmol/mouse dose range, completely blocks the Aβ25-35-induced increase in Aβ1-42 content.[1] |
| Molecular Weight | 511.94 |
| Formula | C24H21ClF3NO4S |
| Cas No. | 290315-45-6 |
Storage & Solubility Information
| Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 27.0 mg/mL (52.7 mM) | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy BMS 299897 | purchase BMS 299897 | BMS 299897 cost | order BMS 299897 | BMS 299897 chemical structure | BMS 299897 in vivo | BMS 299897 in vitro | BMS 299897 formula | BMS 299897 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.